Turing Medical launches new brain mapping and targeting solution

image credit- shutterstock

US-based Turing Medical has announced the launch of Bullsai, its new brain mapping and targeting solution, at the American Society for Stereotactic and Functional Neurosurgery (ASSFN) Biennial Meeting in Nashville, Tenn.

Pending FDA clearance, Bullsai is currently available for research use and marks a milestone in delivering precision brain mapping and targeting to the emerging field of neuromodulation therapy.

Turing has developed an advanced MRI processing pipeline to identify neuroanatomical structures, white matter pathways, and functional brain networks to personalise targeting for individual patients. Turing Medical Bullsai improves neuromodulation therapies by efficiently integrating personalised and precise image-based targeting into clinical workflows. Bullsai’s advanced image processing and analysis pipelines identify treatment targets and provide metrics of target accuracy and confidence to streamline pre-operative planning—saving time, improving patient outcomes, and minimising off-target effects. Clinicians can target specific nodes and networks within an individual’s brain, personalizing treatment and leading to predictable and improved clinical outcomes.

Turing’s automated workflows remove the technical challenges of advanced image-guided targeting, providing clinicians with the information they need to personalise targeting and to quickly and accurately plan and execute image-guided neuromodulation procedures. Turing’s personalised targeting and automated workflows aim to advance neuromodulation therapies by improving patient outcomes and reducing the risk of adverse side effects.